Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Aya Yamamura"'
Autor:
Natsumi Shima, Aya Yamamura, Moe Fujiwara, Taiki Amano, Kazuyuki Matsumoto, Taiga Sekine, Haruka Okano, Rubii Kondo, Yoshiaki Suzuki, Hisao Yamamura
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundPulmonary arterial hypertension (PAH) is a severe and rare disease in the cardiopulmonary system. Its pathogenesis involves vascular remodeling of the pulmonary artery, which results in progressive increases in pulmonary arterial pressure.
Externí odkaz:
https://doaj.org/article/64e8854dd74841dfb209206fd61743f7
Autor:
Masashi Ishida, Aya Yamamura, Moe Fujiwara, Taiki Amano, Mina Ota, Yukari Hikawa, Rubii Kondo, Yoshiaki Suzuki, Yuji Imaizumi, Hisao Yamamura
Publikováno v:
Journal of Pharmacological Sciences, Vol 153, Iss 2, Pp 84-88 (2023)
Pulmonary vessels play a pivotal role in oxygen circulation. We previously demonstrated that pimaric acid (PiMA) activated large-conductance Ca2+-activated K+ (BKCa) channels and inhibited voltage-dependent Ca2+ channels (VDCCs). In the present study
Externí odkaz:
https://doaj.org/article/0b91a9d114b945a9b6096be6f524e175
Publikováno v:
Journal of Pharmacological Sciences, Vol 151, Iss 2, Pp 119-127 (2023)
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease that is characterized by vascular remodeling of the pulmonary artery. PAH remodeling is primarily caused by the excessive proliferation of pulmonary arterial smooth muscle cells
Externí odkaz:
https://doaj.org/article/b4bbf18595244c4b965cc13a2e035ff8
Autor:
Akiko Kawade, Aya Yamamura, Moe Fujiwara, Saki Kobayashi, Shiho Mori, Chihiro Horii, Akari Hiraku, Sayo Suzumura, Kikuo Tsukamoto, Naoki Ohara, Rubii Kondo, Yoshiaki Suzuki, Hisao Yamamura
Publikováno v:
Journal of Pharmacological Sciences, Vol 147, Iss 1, Pp 81-85 (2021)
Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal cardiovascular/lung disease. The incidence rate is affected by age. Monocrotaline (MCT, 60 mg/kg)-treated rats are widely used as an experimental PAH model. Here, we found that y
Externí odkaz:
https://doaj.org/article/b2a81d9e1b344219b4f548fdd892030d
Publikováno v:
Journal of Pharmacological Sciences, Vol 139, Iss 3, Pp 254-257 (2019)
The carcinogenesis and development of prostate cancer are mediated by enhanced Ca2+ signaling. In the present study, the pharmacological profile of the Ca2+-sensing receptor (CaSR) antagonists (calcilytics) was examined in human prostate cancer PC-3
Externí odkaz:
https://doaj.org/article/98b164a323c64cf39919b8dda4566a00
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Vascular endothelial growth factor (VEGF) signaling plays a critical role in the carcinogenesis and tumor development of several cancer types. However, its pathological significance in prostate cancer, one of the most frequent and lethal malignancies
Externí odkaz:
https://doaj.org/article/dd726827400d4811a581a0f1bd37ae50
Autor:
Toshiya Minakata, Akira Inagaki, Aya Yamamura, Hisao Yamamura, Shinji Sekiya, Shingo Murakami
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 12 (2019)
Maintaining Ca2+ homeostasis in lymphatic fluids is necessary for proper hearing. Despite its significance, the mechanisms that maintain the cochlear lymphatic Ca2+ concentrations within a certain range are not fully clarified. We investigated the fu
Externí odkaz:
https://doaj.org/article/18930d91d1ea41f9a3b4ad5f7791b4e3
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138384 (2015)
Idiopathic pulmonary arterial hypertension (IPAH) is a rare and progressive disease of unknown pathogenesis. Vascular remodeling due to excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs) is a critical pathogenic event that lea
Externí odkaz:
https://doaj.org/article/cefccb99a2c1460e89c83d0240b3d7b0
Autor:
Natsumi Shima, Aya Yamamura, Moe Fujiwara, Taiki Amano, Kazuyuki Matsumoto, Taiga Sekine, Haruka Okano, Rubii Kondo, Yoshiaki Suzuki, Hisao Yamamura
Publikováno v:
Frontiers in Cardiovascular Medicine; 2024, p1-14, 14p
Autor:
Taiki Amano, Aya Yamamura, Moe Fujiwara, Seiji Hirai, Rubii Kondo, Yoshiaki Suzuki, Hisao Yamamura
Publikováno v:
Biological and Pharmaceutical Bulletin. 45:1684-1691